Bit like the addition of IL-2 to Azer-cel (which you probably know plays a role naturally in the immune system).
So you're saying, if further investigation on the cholangiocarcinoma patient found small differences in the health of his immune system that gave him an advantage over the other patients, and small tweaks to the treatment or selection of patients (to match said patient) resulted in increases in Vaxinia effacicy, well then you might tell us all that there is circumstantial evidence that patients with a better functioning immune system might have better outcomes.
Am I getting what you are saying? I know the latter re Vaxinia is all hypothetical and on Imugene to prove.
IMU Price at posting:
1.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)